| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
To identify some useful biomarker for early diagnosis of esophageal cancer (EC), we have conducted exome analysis limited to the regions where mutations are found frequently in cancer, in the EC and the corresponding noncancerous tissues as well as in the cohort of gastroenterological cancer patients and healthy volunteers. Four of the 21 gene mutations confirmed in the EC with the next generation sequencer were also confirmed in the non-cancerous tissues as well. Furthermore, 5 genes that could affect the structure and function of the protein were confirmed. These findings suggest the concept of Mutation Signature may be useful as a biomarker of EC. Evaluating the clinical courses of EC surgical cases revealed that serum SCC-Ag monitoring may be useful as a prognostic indicator. Assessment of these potential biomarkers are expected to help the early diagnosis and individualized treatment of EC, to which surgical treatment is invasive, followed by improvement of the outcome.
|
